Buy Rating Affirmed: Jasper Therapeutics' Briquilimab Shows Promising Outlook in Chronic Urticaria Treatment Market
TipRanksApr 24 22:55 ET
Jasper Therapeutics, Inc.'s (NASDAQ:JSPR) Market Cap Dropped US$88m Last Week; Individual Investors Who Hold 36% Were Hit as Were Institutions
Key Insights The considerable ownership by individual investors in Jasper Therapeutics indicates that they collectively have a greater say in management and business strategy A total of 12 investors
Simply Wall StApr 19 06:06 ET
Express News | Jasper Therapeutics Shares Are Trading Higher After Evercore ISI Initiated Coverage on the Stock With an Outperform Rating and $65 Price Target
Moomoo 24/7Apr 3 10:58 ET
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Jasper Therapeutics Initiated at Outperform by Evercore ISI Group
Dow JonesApr 3 07:44 ET
Evercore ISI Group Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $65
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $65.
Analyst UpgradesApr 3 07:34 ET
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
PDF Version REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
Jasper TherapeuticsApr 2 00:00 ET
RBC Starts Jasper Therapeutics at Outperform, Cites Market Opportunity
Seeking AlphaMar 28 16:03 ET
Jasper Therapeutics Initiated at Outperform by RBC Capital
Jasper Therapeutics Initiated at Outperform by RBC Capital
Dow JonesMar 28 04:46 ET
RBC Capital Initiates Coverage On Jasper Therapeutics With Outperform Rating, Announces Price Target of $70
RBC Capital analyst Gregory Renza initiates coverage on Jasper Therapeutics with a Outperform rating and announces Price Target of $70.
Analyst UpgradesMar 28 04:36 ET
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
PDF Version REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
Jasper TherapeuticsMar 21 00:00 ET
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
TipRanksMar 20 09:05 ET
Analysts' Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
TipRanksMar 20 09:00 ET
Jasper Therapeutics Announces First Patient Dosed In Phase 1b/2a SPOTLIGHT Clinical Study Of Briquilimab In Chronic Inducible Urticaria
Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as c
BenzingaMar 19 08:05 ET
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
PDF Version REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel an
Jasper TherapeuticsMar 19 00:00 ET
Express News | TD Cowen Initiates Coverage On Jasper Therapeutics With Outperform Rating
Moomoo 24/7Mar 18 08:34 ET
Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria
TipRanksMar 18 05:45 ET
New Positive Data Presented on Briquilimab Conditioning in Patients With Fanconi Anemia
PDF Version Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplantAll six patients with Fanconi Anemia treated with briquilimab achieved full donor e
Jasper TherapeuticsMar 15 00:00 ET
Jasper Therapeutics(JSPR.US) Officer Sells US$23,792.22 in Common Stocks
$Jasper Therapeutics(JSPR.US)$ Officer Mahal Jeetinder Singh sold 900 shares of Common Stocks on Mar 12, 2024 at an average price of $26.4358 for a total value of $23,792.22.Source: Announcement What
moomoo NewsMar 12 22:13 ET
Express News | Oppenheimer Maintains Outperform on Jasper Therapeutics, Maintains $80 Price Target
Moomoo 24/7Mar 7 08:02 ET
Jasper Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/07/2024 196.3% Oppenheimer $80 → $80 Maintains Outperform 10/12/2023 -77.78% Cantor Fitzgerald → $6 Rei
BenzingaMar 7 08:01 ET
No Data
No Data